QLT Announces Results of Annual General Meeting of Shareholders
June 17 2016 - 4:05PM
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) announces
that, on a vote by ballot, the six incumbent directors of the
Company were re-elected at the Company’s annual general meeting
held on June 17, 2016 (the “Meeting”).
Detailed results of the vote for the election of
directors are as follows:
Nominee |
Votes For |
% |
Votes Withheld |
% |
Jason M. Aryeh |
27,014,511 |
65.29 |
14,361,838 |
34.71 |
Dr. Geoffrey F. Cox, Ph.D |
34,912,443 |
84.38 |
6,463,906 |
15.62 |
Dr. John W. Kozarich, Ph.D |
27,031,870 |
65.33 |
14,344,479 |
34.67 |
Jeffrey A. Meckler |
35,343,607 |
85.42 |
6,032,742 |
14.58 |
Dr. Stephen L. Sabba, M.D. |
27,018,211 |
65.30 |
14,358,138 |
34.70 |
John C. Thomas, Jr. |
28,484,358 |
68.84 |
12,891,991 |
31.16 |
Final voting results on all matters voted on at the
Meeting will be filed on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov.
About QLTQLT is a biotechnology
company dedicated to the development and commercialization of
innovative ocular products that address the unmet medical needs of
patients and clinicians worldwide. We are focused on developing our
synthetic retinoid program for the treatment of certain inherited
retinal diseases.
QLT’s head office is based in Vancouver, Canada and
the Company is publicly traded on NASDAQ Stock Market (symbol:
QLTI) and the Toronto Stock Exchange (symbol: QLT). For more
information about the Company’s products and developments, please
visit our web site at www.qltinc.com.
Certain statements in this press release may
constitute “forward-looking statements” of QLT within the meaning
of the Private Securities Litigation Reform Act of 1995 and
constitute “forward-looking information” within the meaning of
applicable Canadian securities laws. Forward-looking
statements include, but are not limited to: statements which
contain language such as: “assuming,” “prospects,” “goal,”
“future,” “projects,” “potential,” “could,” “may,” “believes,”
“expects,” “hopes” and “outlook.” Forward-looking statements
are predictions only which involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from those expressed in such statements. Many
such risks, uncertainties and other factors are taken into account
as part of our assumptions underlying these forward-looking
statements and include, among others, the following risks,
uncertainties and other factors: the effect that QLT’s
announcements and actions will have on the market price of our
securities; the risk that any transaction pursued by QLT is
unsuccessful; QLT’s development plans, timing and results of the
clinical development of our synthetic retinoid program; the risk
that our assumptions related to continued enrollment trends,
efforts and success, and the associated costs of our synthetic
retinoid program will prove incorrect; the risk that outcomes for
our clinical trials may not be favorable or may be less favorable
than interim/preliminary results disclosed and/or previous trials;
the possibility that interpretations of data produced by one or
more of our clinical trials will vary; the timing, expense and
uncertainty associated with the regulatory approval process for
products to advance through development stages; risks and
uncertainties associated with the safety and effectiveness of our
synthetic retinoid program; risks and uncertainties related to the
scope, validity, and enforceability of our intellectual property
rights and the impact of patents and other intellectual property of
third parties; the Company’s future operating results, which are
uncertain and likely to fluctuate; currency fluctuations; and
general economic conditions and other factors described in detail
in QLT’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other filings with the U.S. Securities and Exchange Commission
and Canadian securities regulatory
authorities. Forward-looking statements are based on the
current expectations of QLT and QLT does not assume any obligation
to update such information to reflect later events or developments
except as required by law.
QLT Inc. Contacts:
Investor Relations/Media
Nathan Riggs/ Jeffrey Taufield
Kekst
212-512-4800
nathan.riggs@kekst.com
jeffrey.taufield@kekst.com
Andrea Rabney/ David Pitts
Argot Partners
212-600-1902
andrea@argotpartners.com
david@argotpartners.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024